Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04269122 · ClinicalTrials.gov registry record
A Study to Assess Plasma Ammonia Time-Normalized Area Under the Curve and Rate of Ureagenesis in Healthy Adult Subjects
A clinical trial of Ornithine Transcarbamylase Deficiency, sponsored by Ultragenyx Pharmaceutical.
- Completed
- Registry status
- 120
- Enrollment target
- 1
- Study location
NCT04269122: Completed study of Ornithine Transcarbamylase Deficiency, sponsored by Ultragenyx Pharmaceutical.
NCT04269122 is a study of Ornithine Transcarbamylase Deficiency that has completed, run by Ultragenyx Pharmaceutical. The registered enrollment target is 120 participants, above the 37-participant average among 4 other Ornithine Transcarbamylase Deficiency trials with a reported enrollment target (224% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04269122, a study of Ornithine Transcarbamylase Deficiency, has completed, sponsored by Ultragenyx Pharmaceutical.
- COMPLETED
- Registry status
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of the study is to characterize 24-hour plasma ammonia levels, characterize urea production rates in healthy normal subjects.
Primary Outcome
Characterization of ammonia production over 24hr
Conditions Studied
Interventions
- OTHER No Intervention
Study Locations (1)
Texas
- PPD Phase 1 Unit - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2019-08-02 |
| Est. Completion | 2020-02-20 |
What the finished NCT04269122 record still lists
NCT04269122 is an observational study that tracks outcomes without assigning an intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, above the 37-participant average among 4 other Ornithine Transcarbamylase Deficiency trials with a reported enrollment target (224% higher).
The record links to 1 condition, with Ornithine Transcarbamylase Deficiency appearing as the primary indexed condition, and to 1 intervention - of which No Intervention is the first listed.
NCT04269122 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04269122 about?
NCT04269122 is a clinical study titled "A Study to Assess Plasma Ammonia Time-Normalized Area Under the Curve and Rate of Ureagenesis in Healthy Adult Subjects". The objective of the study is to characterize 24-hour plasma ammonia levels, characterize urea production rates in healthy normal subjects.
What is the current status of trial NCT04269122?
This trial is currently completed. The enrollment target is 120 participants. The study started on 2019-08-02. Estimated completion is 2020-02-20.
What conditions does trial NCT04269122 study?
This clinical trial studies the following conditions: Ornithine Transcarbamylase Deficiency.
What interventions are being tested in trial NCT04269122?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT04269122?
This trial is sponsored by Ultragenyx Pharmaceutical, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04269122 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ornithine Transcarbamylase Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Liver Disease in Urea Cycle Disorders
RECRUITING
-
An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency
RECRUITING · Phase 1
-
A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD
RECRUITING · Phase 2
-
Hepatic Histopathology in Urea Cycle Disorders
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI